Patents by Inventor Yoshiyuki Okumura
Yoshiyuki Okumura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970751Abstract: The grain-oriented electrical steel sheet according to the present embodiment is a grain-oriented electrical steel sheet having a base steel sheet (1), an intermediate layer (4) disposed to be in contact with the base steel sheet (1), and an insulation coating (3) disposed to be in contact with the intermediate layer (4). The grain-oriented electrical steel sheet according to the present embodiment includes a surface of the base steel sheet (1) having a strain region (D) which extends in a direction intersecting a rolling direction of the base steel sheet (1), and a crystalline phosphorus oxide M2P4O13 present in the insulation coating (3) on the strain region (D) in a cross-sectional view of a surface parallel to the rolling direction and a sheet thickness direction of the base steel sheet (1). (M means at least one or both of Fe and Cr.Type: GrantFiled: January 16, 2020Date of Patent: April 30, 2024Assignee: NIPPON STEEL CORPORATIONInventors: Yoshiyuki Ushigami, Shinji Yamamoto, Hideyuki Hamamura, Takashi Kataoka, Shunsuke Okumura
-
Patent number: 11964963Abstract: This invention relates to novel salts and crystal forms of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1H-1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl]ethan-1-ol, simply abbreviated as Compound A, which is a selective CB2 receptor agonist. The present invention provides a salt of Compound A, a crystal form thereof, a method for preparing the said salt and a pharmaceutical composition thereof and its use. The salts of Compound A of the present invention show good pharmaceutical formulation properties such as high aqueous solubility, good crystallinity, high melting point, good chemical and physical stability, or non-deliquescent.Type: GrantFiled: November 11, 2021Date of Patent: April 23, 2024Assignee: AskAt Inc.Inventors: Yukari Inami, Yoshiyuki Okumura, Tracy Walker
-
Publication number: 20230322737Abstract: This invention relates to novel salts and crystal forms of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1H-1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl]ethan-1-ol, simply abbreviated as Compound A, which is a selective CB2 receptor agonist. The present invention provides a salt of Compound A, a crystal form thereof, a method for preparing the said salt and a pharmaceutical composition thereof and its use. The salts of Compound A of the present invention show good pharmaceutical formulation properties such as high aqueous solubility, good crystallinity, high melting point, good chemical and physical stability, or non-deliquescent.Type: ApplicationFiled: November 11, 2021Publication date: October 12, 2023Applicant: AskAt Inc.Inventors: Yukari INAMI, Yoshiyuki OKUMURA, Tracy WALKER
-
Patent number: 11555023Abstract: This invention relates to a method for preparing a desired isomer of a substituted 2-trifluoromethyl-2H-chromene-3-carboxylic acid, which is characterized by comprising: (a) contacting the substituted 2-trifluoromethyl-2H-chromene-3-carboxylic acid with a chiral amine to form salts, wherein the chiral amine is selected so that the solubility of the amine salt of the undesired substituted 2-trifluoromethyl-2H-chromene-3-carboxylic acid is greater than the amine salt of the desired substituted 2-trifluoromethyl-2H-chromene-3-carboxylic acid, and (b) irradiating the mixture with an ultraviolet (UV) light, wherein the irradiation increases the amount of the less soluble chiral amine salt of the substituted of the 2-trifluoromethyl-2H-chromene-3-carboxylic acid in the mixture.Type: GrantFiled: January 20, 2020Date of Patent: January 17, 2023Assignee: AskAt Inc.Inventors: Yoshiyuki Okumura, Yukari Inami, Bas Dros, Michel Sebastiaan Leeman
-
Publication number: 20220144792Abstract: This invention relates to a method for preparing a desired isomer of a substituted 2-trifluoromethyl-2H-chromene-3-carboxylic acid, which is characterized by comprising: (a) contacting the substituted 2-trifluoromethyl-2H-chromene-3-carboxylic acid with a chiral amine to form salts, wherein the chiral amine is selected so that the solubility of the amine salt of the undesired substituted 2-trifluoromethyl-2H-chromene-3-carboxylic acid is greater than the amine salt of the desired substituted 2-trifluoromethyl-2H-chromene-3-carboxylic acid, and (b) irradiating the mixture with an ultraviolet (UV) light, wherein the irradiation increases the amount of the less soluble chiral amine salt of the substituted of the 2-trifluoromethyl-2H-chromene-3-carboxylic acid in the mixture.Type: ApplicationFiled: January 20, 2020Publication date: May 12, 2022Applicant: AskAt Inc.Inventors: Yoshiyuki OKUMURA, Yukari INAMI, Bas DROS, Michel Sebastiaan LEEMAN
-
Publication number: 20210300921Abstract: The present invention provides N-((4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenethyl)carbamoyl)-4-methylbenzenesulfonamide compositions, and the use thereof for treating a proliferative disorder.Type: ApplicationFiled: July 11, 2019Publication date: September 30, 2021Inventors: Mark MANFREDI, Jeffrey ECSEDY, Alfredo C. CASTRO, Yoshiyuki OKUMURA
-
Patent number: 9447066Abstract: This invention relates to salts and crystal forms of (S)-6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, Compound A, which is cyclooxygenase-2 inhibitor. The present invention provides a salt of compound A, a crystal form thereof, a process for preparing the said salt and a pharmaceutical composition thereof and its use. The salts and/or co-crystals of Compound A of the present invention show good formulation properties such as high aqueous solubility, good intrinsic dissolution, good crystallinity, good thermal stability or low hygroscopicity.Type: GrantFiled: January 6, 2014Date of Patent: September 20, 2016Assignee: AskAt Inc.Inventors: Yoshiyuki Okumura, Yasuhiro Iwata, Toyoharu Numata, Masaki Sudo, Takako Okumura
-
Patent number: 9447065Abstract: The present invention provides a pharmaceutical composition which prevents from decreasing the blood exposure of the third generation coxib-drugs, a process for preparing the said pharmaceutical composition and its use. It has been founded in this invention that adding a basic amine or a basic amino acid, or a cyclodextrin to the third generation coxib-drug can afford a pharmaceutical composition which can prevent from decreasing the blood exposure, AUC and bioavailability. The pharmaceutical composition of the present invention has also good stability, which is useful for drugs. Namely, the technological thought that adding a basic amine or a basic amino acid, or a cyclodextrin to the third generation coxib-drug can prevent from decreasing the blood exposure, AUC and bioavailability has been established in this invention.Type: GrantFiled: October 18, 2012Date of Patent: September 20, 2016Assignee: RaQualia Pharma Inc.Inventors: Yasuhiro Iwata, Kaoru Shimada, Yoshiyuki Okumura, Mayumi Kashino, Hiromitsu Yoshida
-
Publication number: 20150353520Abstract: This invention relates to salts and crystal forms of (S)-6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, Compound A, which is cyclooxygenase-2 inhibitor. The present invention provides a salt of compound A, a crystal form thereof, a process for preparing the said salt and a pharmaceutical composition thereof and its use. The salts and/or co-crystals of Compound A of the present invention show good formulation properties such as high aqueous solubility, good intrinsic dissolution, good crystallinity, good thermal stability or low hygroscopicity.Type: ApplicationFiled: January 6, 2014Publication date: December 10, 2015Applicant: AskAt Inc.Inventors: Yoshiyuki OKUMURA, Yasuhiro IWATA, Toyoharu NUMATA, Masaki SUDO, Takako OKUMURA
-
Publication number: 20140256804Abstract: The present invention provides a pharmaceutical composition which prevents from decreasing the blood exposure of the third generation coxib-drugs, a process for preparing the said pharmaceutical composition and its use. It has been founded in this invention that adding a basic amine or a basic amino acid, or a cyclodextrin to the third generation coxib-drug can afford a pharmaceutical composition which can prevent from decreasing the blood exposure, AUC and bioavailability. The pharmaceutical composition of the present invention has also good stability, which is useful for drugs. Namely, the technological thought that adding a basic amine or a basic amino acid, or a cyclodextrin to the third generation coxib-drug can prevent from decreasing the blood exposure, AUC and bioavailability has been established in this invention.Type: ApplicationFiled: October 18, 2012Publication date: September 11, 2014Applicant: RAQUALIA PHARMA INC.Inventors: Yasuhiro Iwata, Kaoru Shimada, Yoshiyuki Okumura, Mayumi Kashino, Hiromitsu Yoshida
-
Patent number: 8084476Abstract: This invention provides a compound of the formula (I): wherein X represents a carbon atom or the like: Y represents imino, or the like: R1 represents an alkyl group having from 1 to 6 carbon atoms or the like: R2 and R3 independently represents a hydrogen atom or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.Type: GrantFiled: February 10, 2009Date of Patent: December 27, 2011Assignee: Raqualia Pharma Inc.Inventors: Hiroki Koike, Kana Kon-i, Yukari Matsumoto, Kazunari Nakao, Yoshiyuki Okumura, Tatsuya Yamagishi
-
Publication number: 20090163558Abstract: This invention provides a compound of the formula (I): wherein X represents a carbon atom or the like: Y represents imino, or the like: R1 represents an alkyl group having from 1 to 6 carbon atoms or the like: R2 and R3 independently represents a hydrogen atom or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.Type: ApplicationFiled: February 10, 2009Publication date: June 25, 2009Applicant: RaQualia Pharma Inc.Inventors: Hiroki Koike, Kana Kon-i, Yukari Matsumoto, Kazunari Nakao, Yoshiyuki Okumura, Tatsuya Yamagishi
-
Patent number: 7534914Abstract: This invention provides a compound of the formula (I): wherein X represents a carbon atom or the like: Y represents imino, or the like: R1 represents an alkyl group having from 1 to 6 carbon atoms or the like: R2 and R3 independently represents a hydrogen atom or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.Type: GrantFiled: April 29, 2005Date of Patent: May 19, 2009Assignee: ReQualia Pharma Inc.Inventors: Hiroki Koike, Kana Kon-i, Yukari Matsumoto, Kazunari Nakao, Yoshiyuki Okumura, Tatsuya Yamagishi
-
Patent number: 7479564Abstract: This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y1, Y2, Y3 and Y4 are independently selected from N, CH, etc.; R1 is H, C1-8 alkyl, etc.; Q1 is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is C1-6 alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R2 is H, C1-4 alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, C1-4 alkyl, etc.; m is 0, 1 or 2; R3 and R4 are independently selected from H and C1-4 alkyl ; R5 is H, C1-4 alkyl, etc.; Q2 is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.Type: GrantFiled: November 3, 2006Date of Patent: January 20, 2009Assignee: RaQualia Pharma Inc.Inventors: Kazunari Nakao, Yoshiyuki Okumura, Miyako Matsumizu, Naomi Ueno, Yoshinobu Hashizume, Tomoki Kato, Akiyoshi Kawai, Yoriko Miyake, Seiji Nukui, Katsuhiro Shinjyo, Kana Taniguchi
-
Publication number: 20070155732Abstract: This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y1, Y2, Y3 and Y4 are independently selected from N, CH, etc.; R1 is H, C1-8 alkyl, etc.; Q1 is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is C1-6 alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R2 is H, C1-4 alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, C1-4 alkyl, etc.; m is 0, 1 or 2; R3 and R4 are independently selected from H and C1-4 alkyl ; R5 is H, C1-4 alkyl, etc.; Q2 is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.Type: ApplicationFiled: November 3, 2006Publication date: July 5, 2007Inventors: Kazunari Nakao, Yoshiyuki Okumura, Miyako Matsumizu, Naomi Ueno, Yoshinobu Hashizume, Tomoki Kato, Akiyoshi Kawai, Yoriko Miyake, Seiji Nukui, Katsuhiro Shinjyo, Kana Taniguchi
-
Patent number: 7238714Abstract: This invention provides a compound of the formula (I): wherein A represents a phenyl group or the like: B represents an aryl or the like: E represents a 1,4-phenylene group; R1 and R2 independently represent a hydrogen atom or the like: R3 and R4 independently represent a hydrogen atom or the like: R5 represents —CO2H or the like: R6 represents an alkyl group having from 1 to 6 carbon atoms or the like: X represents a methylene group or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.Type: GrantFiled: September 2, 2004Date of Patent: July 3, 2007Assignee: Pfizer Japan, Inc.Inventors: Kazunari Nakao, Seiji Nukui, Yoshiyuki Okumura, Tatsuya Yamagishi
-
Patent number: 7141580Abstract: This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y1, Y2, Y3 and Y4 are independently selected from N, CH, etc.; R1 is H, C1-8 alkyl, etc.; Q1 is a 5–12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5–6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is C1-6 alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R2 is H, C1-4 alkyl, etc.; Z is a 5–12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, C1-4 alkyl, etc.; m is 0, 1 or 2; R3 and R4 are independently selected from H and C1-4 alkyl; R5 is H, C1-4 alkyl, etc.; Q2 is a 5–12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.Type: GrantFiled: February 4, 2004Date of Patent: November 28, 2006Assignee: Pfizer Inc.Inventors: Kazunari Nakao, Yoshiyuki Okumura, Miyako Matsumizu, Naomi Ueno, Yoshinobu Hashizume, Tomoki Kato, Akiyoshi Kawai, Yoriko Miyake, Seiji Nukui, Katsuhiro Shinjyo, Kana Taniguchi
-
Publication number: 20050267170Abstract: This invention provides a compound of the formula (I): wherein X represents a carbon atom or the like: Y represents imino, or the like: R1 represents an alkyl group having from 1 to 6 carbon atoms or the like: R2 and R3 independently represents a hydrogen atom or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.Type: ApplicationFiled: April 29, 2005Publication date: December 1, 2005Inventors: Hiroki Koike, Kana Kon-i, Yukari Matsumoto, Kazunari Nakao, Yoshiyuki Okumura, Tatsuya Yamagishi
-
Publication number: 20050250818Abstract: This invention provides a compound of the formula (I): wherein X represents a carbon atom or the like: Y represents imino, or the like: Z represents a hydrogen atom or the like: R1 represents an alkyl group having from 1 to 6 carbon atoms or the like: R2 and R3 independently represents a hydrogen atom or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.Type: ApplicationFiled: April 29, 2005Publication date: November 10, 2005Inventors: Hiroki Koike, Yukari Matsumoto, Kazunari Nakao, Yoshiyuki Okumura, Tatsuya Yamagishi
-
Publication number: 20050065188Abstract: This invention provides a compound of the formula (I): wherein A represents a phenyl group or the like: B represents an aryl or the like: E represents a 1,4-phenylene group; R1 and R2 independently represent a hydrogen atom or the like: R3 and R4 independently represent a hydrogen atom or the like: R5 represents —CO2H or the like: R6 represents an alkyl group having from 1 to 6 carbon atoms or the like: X represents a methylene group or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.Type: ApplicationFiled: September 2, 2004Publication date: March 24, 2005Inventors: Kazunari Nakao, Seiji Nukui, Yoshiyuki Okumura, Tatsuya Yamagishi